Nattokinase Breaks the Vicious Loop Between Inflammation, Oxidative Stress, and Coagulation via LPS-Induced Macrophage Signaling

This experimental study used LPS-stimulated macrophage cell culture and in vivo models to investigate nattokinase’s capacity to interrupt the coupled positive feedback between inflammation, oxidative stress, and coagulation — three processes that mutually amplify one another in the pathogenesis of thrombosis and atherosclerosis.

Nattokinase inhibited LPS-induced activation of TLR4 and the downstream NOX2-ROS pathway, reduced NF-κB signaling and pro-inflammatory cytokines (TNF-α, IL-6), suppressed PAI-1 production (consistent with its established fibrinolytic profile), and decreased fibrin deposition in glomeruli. The authors describe nattokinase as a “multi-target” agent breaking the inflammation-oxidative stress-coagulation loop.

The mechanistic characterization is sophisticated, and the identified pathways — TLR4, NF-κB, NOX2 — are genuine drivers of vascular inflammation and thrombosis. However, the experimental design (LPS-stimulated macrophages and in vivo inflammatory models) is far removed from the clinical scenario of spontaneous coronary plaque rupture and thrombosis.

The consistent unresolved question for all nattokinase studies remains: does orally ingested nattokinase reach systemic circulation at concentrations sufficient to recapitulate these mechanistic effects in vivo? The answer from human pharmacokinetic studies is that this is not clearly established. Without confirmed systemic bioavailability, the multi-target anti-thrombotic mechanisms described in cell and animal models cannot be assumed to apply in humans.

We rate the evidence moderate for basic science. A mechanistically rich experimental study characterizing nattokinase’s anti-inflammatory and anti-coagulant signaling effects — important hypothesis-generating data that requires human pharmacokinetic and clinical outcome validation to become clinically applicable.